Good news of signing the contract

  • Categories:News center
  • Author:
  • Origin:
  • Time of issue:2022-12-20 10:43
  • Views:

(Summary description)On December 19th, 2022, Rico International (Beijing) Medicine Technology Co., Ltd. reached a strategic consensus with Japan's Ribomic Co., Ltd. and Shanghai Huirui Medical Devices Co., Ltd. on the clinical development of RBM-007 with age-related macular degeneration (AMD), and signed a tripartite joint venture company framework agreement to jointly promote the clinical development, promotion and sales of this drug in Greater China.

Good news of signing the contract

(Summary description)On December 19th, 2022, Rico International (Beijing) Medicine Technology Co., Ltd. reached a strategic consensus with Japan's Ribomic Co., Ltd. and Shanghai Huirui Medical Devices Co., Ltd. on the clinical development of RBM-007 with age-related macular degeneration (AMD), and signed a tripartite joint venture company framework agreement to jointly promote the clinical development, promotion and sales of this drug in Greater China.

  • Categories:News center
  • Author:
  • Origin:
  • Time of issue:2022-12-20 10:43
  • Views:
Information


Good news of signing the contract

            On December 19th, 2022, Rico International (Beijing) Medicine Technology Co., Ltd. reached a strategic consensus with Japan's Ribomic Co., Ltd. and Shanghai Huirui Medical Devices Co., Ltd. on the clinical development of RBM-007 with age-related macular degeneration (AMD), and signed a tripartite joint venture company framework agreement to jointly promote the clinical development, promotion and sales of this drug in Greater China.

          About RBM-007 
             RBM-007 is used to treat AMD, and has a new pharmacological effect of inhibiting angiogenesis and scar formation in AMD by inhibiting the function of fibroblast proliferation factor 2 (FGF2). The clinical development of RBM-007 has been carried out in the United States, and three phase II clinical trials have been completed. According to the clinical trial results, cases with improved symptoms were found in clinical trials led by doctors targeting untreated patients. At present, in-depth development is continuing for untreated patients.


            In the future, after the establishment of the joint venture company, the three parties will also discuss and introduce the existing varieties and varieties under research of Ribomic Co., Ltd. of Japan to the three party joint venture company established in China for development and sales, so as to continue to provide Chinese people with high-quality foreign drugs and equipment.

December 20th, 2022             

Scan the QR code to read on your phone

Previous: None
Next: None
Previous: None
Next: None

信息发送SAUNDERS

WRITE A MESSAGE TO US

Username used for comment:
客户留言
Description:
验证码
客户留言
code

Rico International (Beijing) Medicine Technology Co., Ltd.

Add:   Room 709, Building 10, Wanda Plaza, No. 93, Jianguo Road, Chaoyang District, Beijing

Rico International (Beijing) Medicine Technology Co., Ltd.    copyright ©2020       京ICP备2020042821号

瑞科国际(北京)医药技术有限公司